Standout Papers

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Pa... 1990 2026 2002 2014 5.6k
  1. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels (1996)
    Frank M. Sacks, Marc A. Pfeffer et al. New England Journal of Medicine
  2. Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction (1992)
    Marc A. Pfeffer, Eugene Braunwald et al. New England Journal of Medicine
  3. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes (2004)
    Christopher P. Cannon, Eugene Braunwald et al. New England Journal of Medicine
  4. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. (1990)
    Marc A. Pfeffer, Eugene Braunwald Circulation
  5. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events (2009)
    Arthur J. Moss, William J. Hall et al. New England Journal of Medicine
  6. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial (2003)
    Salim Yusuf, Marc A. Pfeffer et al. The Lancet
  7. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial (2003)
    John J.V. McMurray, Jan Östergren et al. The Lancet
  8. C-Reactive Protein Levels and Outcomes after Statin Therapy (2005)
    Paul M. Ridker, Christopher P. Cannon et al. New England Journal of Medicine
  9. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (2015)
    Marc A. Pfeffer, Brian Claggett et al. New England Journal of Medicine
  10. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both (2003)
    Marc A. Pfeffer, John J.V. McMurray et al. New England Journal of Medicine
  11. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update (2006)
    Sidney C. Smith, Jerilyn K. Allen et al. Circulation
  12. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention (2005)
    Scott D. Solomon, John J.V. McMurray et al. New England Journal of Medicine
  13. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction (2004)
    Nagesh S. Anavekar, John J.V. McMurray et al. New England Journal of Medicine
  14. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 (2020)
    Muthiah Vaduganathan, Orly Vardeny et al. New England Journal of Medicine
  15. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme (2003)
    Marc A. Pfeffer, Karl Swedberg et al. The Lancet
  16. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial (2006)
    Janice Pogue, Robert G. Hart et al. The Lancet
  17. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein (1999)
    Paul M. Ridker, Nader Rifai et al. Circulation
  18. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial (2003)
    Christopher B. Granger, John J.V. McMurray et al. The Lancet
  19. Myocardial infarct size and ventricular function in rats. (1979)
    Marc A. Pfeffer, J M Pfeffer et al. Circulation Research
  20. Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels (1998)
    Paul M. Ridker, Nader Rifai et al. Circulation
  21. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients (2000)
    Marcus Flather, Salim Yusuf et al. The Lancet
  22. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes (2004)
    James A. de Lemos, Michael A. Blazing et al. JAMA
  23. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease (2003)
    Mark J. Sarnak, Andrew S. Levey et al. Hypertension
  24. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes (2012)
    Hans‐Henrik Parving, Barry M. Brenner et al. New England Journal of Medicine
  25. Effect of Captopril on Progressive Ventricular Dilatation after Anterior Myocardial Infarction (1988)
    Marc A. Pfeffer, Gervasio A. Lamas et al. New England Journal of Medicine
  26. A Prospective Evaluation of an Angiotensin-Converting–Enzyme Gene Polymorphism and the Risk of Ischemic Heart Disease (1995)
    Klaus Lindpaintner, Marc A. Pfeffer et al. New England Journal of Medicine
  27. Elevation of Tumor Necrosis Factor-α and Increased Risk of Recurrent Coronary Events After Myocardial Infarction (2000)
    Paul M. Ridker, Nader Rifai et al. Circulation
  28. Predictors of mortality and morbidity in patients with chronic heart failure (2005)
    Stuart Pocock, Duolao Wang et al. European Heart Journal
  29. Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure (2007)
    G. Michael Felker, Larry A. Allen et al. Journal of the American College of Cardiology
  30. Sex Differences in the Management of Coronary Artery Disease (1991)
    Richard M. Steingart, Milton Packer et al. New England Journal of Medicine
  31. Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure (2006)
    Hans L. Hillege, Dorothea Nitsch et al. Circulation
  32. Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels (1998)
    Ronald Goldberg, Margot J. Mellies et al. Circulation
  33. Relation Between Serum Phosphate Level and Cardiovascular Event Rate in People With Coronary Disease (2005)
    Marcello Tonelli, Frank M. Sacks et al. Circulation
  34. A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery Disease (2009)
    Torbjørn Omland, James A. de Lemos et al. New England Journal of Medicine
  35. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. (1985)
    J M Pfeffer, Marc A. Pfeffer et al. Circulation Research
  36. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. (1994)
    Martin St. John Sutton, Marc A. Pfeffer et al. Circulation
  37. Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease (2008)
    Marcello Tonelli, Frank M. Sacks et al. Circulation
  38. Controversies in ventricular remodelling (2006)
    Lionel H. Opie, Patrick Commerford et al. The Lancet
  39. Ventricular Remodeling after Myocardial Infarction (1993)
    Gary F. Mitchell, Gervasio A. Lamas et al. Advances in experimental medicine and biology
  40. Heart failure (2005)
    John J.V. McMurray, Marc A. Pfeffer The Lancet
  41. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients (2005)
    Scott D. Solomon, Nagesh S. Anavekar et al. Circulation
  42. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. (1985)
    Marc A. Pfeffer, J M Pfeffer et al. Circulation
  43. The Heart in Hypertension (1992)
    Edward D. Fröhlich, Carl S. Apstein et al. New England Journal of Medicine
  44. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. (1986)
    Raymond G. McKay, Marc A. Pfeffer et al. Circulation
  45. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update (2001)
    Sidney C. Smith, Steven N. Blair et al. Journal of the American College of Cardiology
  46. Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both (2005)
    Scott D. Solomon, John J.V. McMurray et al. New England Journal of Medicine
  47. Heart Failure With Preserved Ejection Fraction In Perspective (2019)
    Marc A. Pfeffer, Amil M. Shah et al. Circulation Research
  48. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update (2006)
    Sidney C. Smith, Jerilyn K. Allen et al. Journal of the American College of Cardiology
  49. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme (2008)
    Michael R. MacDonald, Mark C. Petrie et al. European Heart Journal
  50. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction (2015)
    Scott D. Solomon, Brian Claggett et al. European Heart Journal
  51. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone (2015)
    Amil M. Shah, Brian Claggett et al. Circulation
  52. Heart Failure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction Spectrum (2018)
    Lars H. Lund, Brian Claggett et al. European Journal of Heart Failure

Immediate Impact

1 by Nobel laureates 5 from Science/Nature 238 standout
Sub-graph 1 of 14

Citing Papers

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
2018 Standout
5 intermediate papers

Works of Marc A. Pfeffer being referenced

Analysing Recurrent Hospitalizations in Heart Failure: A Review of Statistical Methodology, with Application to CHARM-Preserved
2013
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
2004 Standout
and 5 more

Author Peers

Author Last Decade Papers Cites
Marc A. Pfeffer 62884 25888 17255 593 94.5k
William B. Kannel 69673 22477 25140 475 125.2k
Daniel Levy 88384 24628 18947 807 138.9k
John J.V. McMurray 84097 22055 29299 1.5k 126.4k
Christopher P. Cannon 37120 27182 13675 869 65.6k
Peter W.F. Wilson 34252 30320 29024 632 107.0k
Scott D. Solomon 62893 13122 12767 1.1k 89.8k
Eugene Braunwald 49596 29906 12024 687 75.0k
Martin G. Larson 51911 12342 9351 580 86.7k
Gregg C. Fonarow 76391 17156 9723 1.8k 109.2k
Deepak L. Bhatt 55509 38853 22590 2.0k 103.4k

All Works

Loading papers...

Rankless by CCL
2026